Regarding IL-10 expression, no statistical differences were found in HPEpiC cell line; in LNCaP cell line, the UC-MSC treatment enhance this gene expression in 9.2 ± 4.9% and in both PCa cell lines (PC3 and LNCaP), CBS treatment led to an increase of this gene expression in 5.2 ± 4.8% for PC3 and in 7.7 ± 7.5% for LNCaP (p < 0.05 vs. control group). This evidence concerns the gene IL10 and posterior cortical atrophy.